RecruitingPhase 3NCT03955445

Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

Studying C3 glomerulonephritis

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Novartis Pharmaceuticals
Principal Investigator: Novartis Pharmaceuticals
Novartis Pharmaceuticals
Intervention: LNP023(drug)
Enrollment: 225 enrolled
Eligibility: 12-100 years · All sexes
Timeline: 2019 – 2036

Study locations (30)

Childrens Hospital Colorado, Aurora, Colorado, United States
Georgia Nephrology Research Inst, Lawrenceville, Georgia, United States
University of Iowa Health Care, Iowa City, Iowa, United States
University of Minnesota, Minneapolis, Minnesota, United States
Col Uni Med Center New York Presby, New York, New York, United States
Novartis Investigative Site, CABA, Buenos Aires, Argentina
Novartis Investigative Site, Buenos Aires, Argentina
Novartis Investigative Site, Belo Horizonte, Minas Gerais, Brazil
Novartis Investigative Site, Porto Alegre, Rio Grande do Sul, Brazil
Novartis Investigative Site, Botucatu, São Paulo, Brazil
Novartis Investigative Site, São Paulo, São Paulo, Brazil
Novartis Investigative Site, Salvador, Brazil
Novartis Investigative Site, Toronto, Ontario, Canada
Novartis Investigative Site, Beijing, China
Novartis Investigative Site, Shanghai, China
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03955445 on ClinicalTrials.gov

Other trials for C3 glomerulonephritis

Additional recruiting or active studies for the same condition.

See all trials for C3 glomerulonephritis →

← Back to all trials